CRISPR Therapeutics (NASDAQ:CRSP) Given New $47.00 Price Target at The Goldman Sachs Group
CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) had its price target lowered by equities research analysts at The Goldman Sachs Group from $53.00 to $47.00 in a research report issued on Thursday,Benzinga reports. The brokerage presently has a “neutral” rating on the stock. The Goldman Sachs Group’s target price suggests a potential upside of 31.95% […]
More Stories
Foundations Investment Advisors LLC Increases Stock Holdings in iShares Core MSCI EAFE ETF (BATS:IEFA)
Foundations Investment Advisors LLC increased its holdings in shares of iShares Core MSCI EAFE ETF (BATS:IEFA – Free Report) by...
Schwab International Equity ETF (NYSEARCA:SCHF) Stake Lowered by Meeder Advisory Services Inc.
Meeder Advisory Services Inc. reduced its stake in shares of Schwab International Equity ETF (NYSEARCA:SCHF – Free Report) by 4.8%...
Invesco S&P 500 Quality ETF (NYSEARCA:SPHQ) Shares Bought by Geneos Wealth Management Inc.
Geneos Wealth Management Inc. raised its stake in Invesco S&P 500 Quality ETF (NYSEARCA:SPHQ – Free Report) by 138.0% during...
Howard Capital Management Inc. Purchases 792 Shares of iShares 1-3 Year Treasury Bond ETF (NASDAQ:SHY)
Howard Capital Management Inc. raised its position in shares of iShares 1-3 Year Treasury Bond ETF (NASDAQ:SHY – Free Report)...
Arkadios Wealth Advisors Raises Stake in iShares Core MSCI EAFE ETF (BATS:IEFA)
Arkadios Wealth Advisors raised its position in shares of iShares Core MSCI EAFE ETF (BATS:IEFA – Free Report) by 9.6%...
Arkadios Wealth Advisors Acquires 10,070 Shares of Vanguard Small-Cap Value ETF (NYSEARCA:VBR)
Arkadios Wealth Advisors raised its holdings in shares of Vanguard Small-Cap Value ETF (NYSEARCA:VBR – Free Report) by 140.9% in...